SR18662

立即咨询

SR18662

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

2505001-62-5

包装与价格：

包装	价格(元)
10 mM * 1 mL in DMSO	电议
5mg	电议
10mg	电议
50mg	电议
100mg	电议
200mg	电议
500mg	电议

产品介绍

SR18662 是一种有效的Kruppel-like factor 5 (KLF5)的抑制剂，IC₅₀为 4.4 nM，ML264 (HY-19994) 的类似物。SR18662 可用于结直肠癌的相关研究。

生物活性

SR18662 is a potent inhibitor ofKrüppel-like factor five (KLF5)with anIC₅₀ of 4.4 nM and an analogue of ML264 (HY-19994) with improved inhibitory potency against colorectalcancercells. SR18662 can be used for the study of colorectalcancer^[1].

IC₅₀& Target

IC50: 4.4 nM (KLF5)^[1]

体外研究
(In Vitro)

SR18662 (0-10 μM; 24-72 hours) significantly reduces growth and proliferation of CRC cells as compared to treatment with vehicle control, ML264 (HY-19994). It shows improved efficacy in reducing viability of multiple CRC cell lines^[1].
SR18662 (10 μM; 24-72 hours) shows a significant increase in the number of apoptotic cells at both early and late states in DLD-1 and HCT116 cells^[1].
SR18662 (1 μM; 72 hours) reduces the expression of cyclins (cyclins E, A2, and B1) and components of MAPK (p-Erk) and WNT signaling pathways (p-GSK3 β) in cells^[1].

Cell Viability Assay^[1]

Cell Line:	CRC cells
Concentration:	0-10 μM
Incubation Time:	24 hours, 48 hours, 72 hours
Result:	Induced anti-tumor activity in colorectal cancer cell lines.

Apoptosis Analysis^[1]

Cell Line:	DLD-1 and HCT116 cells
Concentration:	10 μM
Incubation Time:	24 hours, 48 hours, 72 hours
Result:	Increased apoptosis of colorectal cancer cell lines.

Western Blot Analysis^[1]

Cell Line:	DLD-1 and HCT116 cells
Concentration:	1 μM
Incubation Time:	72 hours
Result:	Reduced levels of cyclins E, A2, and B1 inhibits activity of MAPK, WNT/β-catenin signaling pathways and decreases the levels of cyclins.

体内研究
(In Vivo)

SR18662 (intraperitoneal injection; 5-10 mg/kg; daily or twice daily; 5 days injection, days break, and 5 days) significantly reduces the growth of tumors in a mouse xenograft model^[1].

Animal Model:	Nude mice with DLD-1 cells^[1]
Dosage:	5 mg/kg; 10 mg/kg; 25 mg/kg
Administration:	Intraperitoneal injection; 5mg/kg daily, 5mg/kg twice a day,10 mg/kg daily, 10 mg/kg twice per day, 25mg/kg daily, and 25 mg/kg twice per day; 5 days of injections, 2 days break, and 5 days of injections
Result:	Caused a significant dose-dependent inhibition of xenograft growth in mice.

分子量

420.31

性状

Solid

Formula

C₁₆H₁₉Cl₂N₃O₄S

CAS 号

2505001-62-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 125 mg/mL(297.40 mM;Need ultrasonic)

配制储备液

浓度溶剂体积质量

1 mg

5 mg

10 mg

1 mM	2.3792 mL	11.8960 mL	23.7920 mL
5 mM	0.4758 mL	2.3792 mL	4.7584 mL
10 mM	0.2379 mL	1.1896 mL	2.3792 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.
请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline)
Solubility: 2.08 mg/mL (4.95 mM); Clear solution; Need ultrasonic
此方案可获得 2.08 mg/mL (4.95 mM) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
2.
请依序添加每种溶剂： 10% DMSO 90%corn oil
Solubility: ≥ 2.08 mg/mL (4.95 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.95 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在本网站选购。